fda ruling on glp 1 says that the GLP-1 shortage is over Hims Inc. - Novo Nordisk's
Description
Novo Nordisks strong clinical data and successful commercialization of its GLP-1 receptor agonist portfolio have established it as a market leader

10.2337/dc22-1889 [DOI] [PMC free article] [PubMed] [Google Scholar] 71

Theres a slew of side effects that come with taking GLP-1s

Oral GLP-1s: Eli Lillys Next Big Revenue Stream

Acta Histochem

Mol Cell Endocrinol 418:4254 Lorenz M, Evers A, Wagner M (2013) Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity
